Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
Healthcare
$84.83 -1.25%
-$1.03 today
- Market cap
- $4.78B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
52W Low $16.64High $96.50
Volume 0.89M
Average 0.82M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$129.06M
FY 2025 · Annual
Investing Cash Flow
-$122.83M
FY 2025 · Annual
Financing Cash Flow
$280.13M
FY 2025 · Annual
+9.6% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.14M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Depreciation & Amortization | 2.02M | 147K | 355K | 412K | 428K |
| Deferred Income Tax | 0 | 0 | (661K) | 0 | 0 |
| Stock-Based Compensation | 0 | 1.52M | 2.9M | 12.89M | 22.79M |
| Change in Working Capital | (1.53M) | (1.65M) | 4.86M | (351K) | 16.73M |
| Accounts Receivables | 0 | (4.16M) | 5.16M | 0 | 755K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (720K) | 2.28M | 661K | 8.19M | 11.28M |
| Other Working Capital | (806K) | 229K | (959K) | (8.54M) | 4.69M |
| Other Non-Cash Items | 11.11M | (606K) | (762K) | (6.17M) | (6.67M) |
| Operating Cash Flow | (59.53M) | (29.07M) | (36.86M) | (78.18M) | (129.06M) |
| Capital Expenditures | (1.26M) | (139K) | (110K) | (105K) | (213K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (45.31M) | (61.68M) | (57.42M) | (413.71M) | (435.01M) |
| Sales of Investments | 90M | 2M | 77.79M | 127M | 312.39M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 43.43M | (59.82M) | 20.25M | (286.81M) | (122.83M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 89.6M | 0 | 72M | 269.2M | 280.13M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (3.32M) | 61.57M | (13.58M) | 0 |
| Financing Cash Flow | 89.6M | 96.68M | 133.57M | 255.62M | 280.13M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 73.5M | 7.79M | 116.97M | (109.37M) | 28.23M |
| Free Cash Flow | (60.8M) | (29.21M) | (36.97M) | (78.29M) | (129.27M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$162.3M
+ D&A$428.0K
+ Stock-Based Comp$22.8M
+ Deferred Tax$0
+ Working Capital$16.7M
- Other Non-Cash-$6.7M
= Operating Cash Flow-$129.1M
- Capex-$213.0K
= Free Cash Flow-$129.3M
Analysis
FY2025 free cash flow is -$129.3M. FCF conversion is 79.6% of net income. Operating cash flow was -$129.1M, with capex of -$213.0K. The largest bridge item is Stock-Based Comp at $22.8M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| SC 13G | SC 13G filing | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 18, 2026 |
Does DNTH generate free cash flow?
Dianthus Therapeutics, Inc. (DNTH) generated -$129.27M of free cash flow in fiscal 2025.
How much operating cash flow does DNTH produce?
Operating cash flow was -$129.06M, before capital expenditures of $213,000.00.
Continue the stock analysis
Jump to another research area for this company.